Pilot Study Evaluating the Expression of ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer.

Trial Profile

Pilot Study Evaluating the Expression of ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase 0

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Mar 2017 Status changed from discontinued to withdrawn prior to enrolment.
    • 20 Jul 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 21 Oct 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top